HUTCHMED has commenced the P-III (RAPHAEL) study to assess the safety & efficacy of HMPL-306 alone for treating IDH1 and/or IDH2 mutated r/r acute myeloid leukemia (AML) patients (n=~320) in China. The first patient was dosed on May 11, 2024
The P-III (RAPHAEL) trial followed the P-I study investigating the safety, PK/PD & efficacy of HMPL-306, the dose-escalation stage results of which were highlighted at EHA 2023. The dose expansion stage data among 50 patients, depicting favorable CRs at RP2D, will be highlighted at EHA 2024
HMPL-306 is a dual-inhibitor targeting IDH1 and IDH2 enzymes, whose mutations are responsible for some hematological malignancies, gliomas & solid tumors, particularly AML
Ref: HUTCHMED | Image: HUTCHMED
Related News:- The NMPA Accepts HUTCHMED and Innovent’s NDA for Fruquintinib Plus Sintilimab with Priority Review to Treat Endometrial Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
